Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1248-1249, 2003; 10.1373/49.8.1248
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giannitsis, E.
Right arrow Articles by Katus, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giannitsis, E.
Right arrow Articles by Katus, H. A.
Related Collections
Right arrow Heart Health and the Clinical Laboratory
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2003;49:1248-1249.)
© 2003 American Association for Clinical Chemistry, Inc.

Editorials

99th Percentile and Analytical Imprecision of Troponin and Creatine Kinase-MB Mass Assays: An Objective Platform for Comparison of Assay Performance

Evangelos Giannitsis1 and Hugo A. Katus1,a

1 Abteilung für Innere Medizin III, Medizinische Klinik und Poliklinik, Universitäts-Klinikum Heidelberg, D-69115 Heidelberg, Germany

aAddress correspondence to this author at: Abt. Innere Medizin III, Medizinische Klinik, Bergheimer Strasse 58, D-69115 Heidelberg, Germany. E-mail hugo_katus@med.uni-heidelberg.de.

The first 20% of the full text of this article appears below.

Cardiac troponins in blood are the most sensitive and specific biochemical markers of myocardial damage and are paramount for classification, risk stratification, and customized therapy in patients with acute coronary syndromes (1)(2). Despite the overt advantages, some important obstacles to troponin analysis and interpretation have remained, such as assay standardization, interference, preanalytical variability, and imprecision (3).

Introduction of the 99th percentile reference limit for the diagnosis of myocardial infarction by the European Society of Cardiology/American College of Cardiology (ESC/ACC) Consensus Committee (4)(5) has largely been driven by the demonstration that even the lowest detectable amounts of cardiac troponins in blood are associated with increased cardiac risk (6)(7)(8). Conversely, patients with any detectable troponins benefit from early coronary or pharmacologic intervention (6)(7)(8). Implementation of the new definition of acute myocardial infarction is not trivial because it will almost double the number of patients with . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 J Am Coll CardiolHome page
D. A. Waxman, S. Hecht, J. Schappert, and G. Husk
A Model for Troponin I as a Quantitative Predictor of In-Hospital Mortality
J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1755 - 1762.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
M. Kemp, J. Donovan, H. Higham, and J. Hooper
Biochemical markers of myocardial injury
Br. J. Anaesth., July 1, 2004; 93(1): 63 - 73.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.